Switch theme
Sign up to access all valuation multiples
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
2011
33
Last FY Revenue n/a
Last FY EBITDA -$18.0M
$142M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Eupraxia Pharmaceuticals achieved revenue of n/a and an EBITDA of -$18.0M.
Eupraxia Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Eupraxia Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$18.0M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$29.9M | XXX | -$19.5M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$28.9M | XXX | -$18.4M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Eupraxia Pharmaceuticals's stock price is CAD 5 (or $4).
Eupraxia Pharmaceuticals has current market cap of CAD 191M (or $138M), and EV of CAD 197M (or $142M).
See Eupraxia Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $142M | $138M | XXX | XXX | XXX | XXX | $-0.71 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Eupraxia Pharmaceuticals has market cap of $138M and EV of $142M.
Eupraxia Pharmaceuticals's trades at n/a EV/Revenue multiple, and -7.9x EV/EBITDA.
Equity research analysts estimate Eupraxia Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Eupraxia Pharmaceuticals has a P/E ratio of -4.8x.
See valuation multiples for Eupraxia Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $138M | XXX | $138M | XXX | XXX | XXX |
| EV (current) | $142M | XXX | $142M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -7.9x | XXX | XXX | XXX |
| EV/EBIT | -4.8x | XXX | -7.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.8x | XXX | -7.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -6.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEupraxia Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.6M for the same period.
Eupraxia Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Eupraxia Pharmaceuticals's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Eupraxia Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Eupraxia Pharmaceuticals acquired XXX companies to date.
Last acquisition by Eupraxia Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Eupraxia Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Eupraxia Pharmaceuticals founded? | Eupraxia Pharmaceuticals was founded in 2011. |
| Where is Eupraxia Pharmaceuticals headquartered? | Eupraxia Pharmaceuticals is headquartered in Canada. |
| How many employees does Eupraxia Pharmaceuticals have? | As of today, Eupraxia Pharmaceuticals has 33 employees. |
| Who is the CEO of Eupraxia Pharmaceuticals? | Eupraxia Pharmaceuticals's CEO is Dr. James A. Helliwell, M.D.. |
| Is Eupraxia Pharmaceuticals publicy listed? | Yes, Eupraxia Pharmaceuticals is a public company listed on TSE. |
| What is the stock symbol of Eupraxia Pharmaceuticals? | Eupraxia Pharmaceuticals trades under EPRX ticker. |
| When did Eupraxia Pharmaceuticals go public? | Eupraxia Pharmaceuticals went public in 2021. |
| Who are competitors of Eupraxia Pharmaceuticals? | Similar companies to Eupraxia Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Eupraxia Pharmaceuticals? | Eupraxia Pharmaceuticals's current market cap is $138M |
| Is Eupraxia Pharmaceuticals profitable? | Yes, Eupraxia Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
